MedTrace Logo

Comparison of Cefdinir and Cefdinir/Clavulanic Acid Combination in Adults

NCT03400735 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-01-17

No results posted yet for this study

Summary

It is planned to compare the efficacy and safety of cefdinir and cefdinir/clavulanic acide treatments in acute exacerbation of chronic bronchitis (AECB) and community-acquired pneumoniae (CAP) patients.

Conditions

  • Acute Exacerbation of Chronic Bronchitis
  • Community-Acquired Pneumoniae

Interventions

COMBINATION_PRODUCT

Cefdinir/clavulanic acide 300/125 mg film-coated tablets

Cefdinir is already an approved drug. In this study, developed cefdinir/clavulanic acide combination will be compared against to cefdinir alone.

DRUG

Cefdinir 300Mg Capsule

Cefdinir is used as comparator

Sponsors & Collaborators

  • Neutec Ar-Ge San ve Tic A.Ş

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2018-04-01
Completion
2018-08-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03400735 on ClinicalTrials.gov